Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997780 | 0.84 | CRBN (0.38) | CRBN | |
| SCHEMBL7539678 | 0.78 | CRBN (0.42) | CRBNOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL6236013 | 0.74 | OPRM1 (0.46) | CRBNHSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL28323316 | 0.74 | OPRM1 (0.43) | CRBNHSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL6235625 | 0.72 | OPRM1 (0.49) | CRBNHSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL1810703 | 0.71 | PARP1 (0.37) | CRBNOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL25342561 | 0.70 | PIK3CA (0.39) | CRBNPIK3CAMTOR | |
| SCHEMBL25974606 | 0.70 | PIK3CA (0.39) | CRBNPIK3CAMTOR | |
| SCHEMBL16061182 | 0.70 | IL4I1 (0.35) | IL4I1HSD11B1SCN9ASCN10AOPRM1 | |
| SCHEMBL16060642 | 0.70 | IL4I1 (0.35) | IL4I1HSD11B1SCN9ASCN10AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | CRBN 710/4885PIK3CA 2692/4885MTOR 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.